ArticleJournal of biomedical research2024

Anlotinib reverses osimertinib resistance by inhibiting epithelial-to-mesenchymal transition and angiogenesis in non-small cell lung cancer.

Liting Lyu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.